This segment focuses on the research, development, and clinical trials of autologous CAR-T cell therapies for treating blood cancers. CARsgen is developing CT053, an autologous CAR-T product candidate in a pivotal Phase II trial for relapsed/refractory multiple myeloma in China. The company utilizes advanced cell engineering and immunotherapy techniques to modify T cells to recognize and eliminate cancer cells. This segment addresses significant unmet needs in hematological malignancies, aiming to improve patient outcomes and provide potentially curative treatments. Market positioning is based on innovative CAR-T technology and clinical trial results. Future opportunities include expanding the indications and geographic reach of approved therapies, as well as developing next-generation CAR-T products. Regulatory and clinical aspects involve rigorous clinical trials and seeking regulatory approvals in China and the United States. Partnerships may be formed to accelerate clinical development and commercialization.

This segment concentrates on developing CAR-T cell therapies for solid tumors, which present unique challenges due to the tumor microenvironment and antigen heterogeneity. CARsgen is developing CT041, an autologous CAR-T product candidate in Phase Ib/II clinical trials for advanced gastric/gastroesophageal junction cancer and pancreatic cancer in China, and in Phase Ib clinical trials in the United States. The company employs advanced technologies to enhance CAR-T cell efficacy and persistence in the tumor microenvironment. This segment addresses a critical need for effective treatments for solid tumors, which often have poor prognosis. Market positioning is based on targeting specific tumor antigens and clinical trial data. Future opportunities include expanding the pipeline to include additional solid tumor types and developing combination therapies. Regulatory and clinical aspects involve conducting clinical trials and seeking regulatory approvals. Partnerships may be established to accelerate clinical development and commercialization.

This segment focuses on the development of humanized monoclonal antibody product candidates for the treatment of solid tumors. CARsgen is developing AB011, a humanized monoclonal antibody product candidate in Phase I clinical trials for the treatment of CLDN18.2 positive solid tumors in China. The company utilizes advanced antibody engineering and screening technologies to identify and develop antibodies with high specificity and efficacy. This segment addresses the need for targeted therapies for solid tumors. Market positioning is based on the development of novel antibody therapeutics and clinical trial results. Future opportunities include expanding the pipeline to include additional antibody candidates and developing combination therapies. Regulatory and clinical aspects involve conducting clinical trials and seeking regulatory approvals. Partnerships may be formed to accelerate clinical development and commercialization.